Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

A. Woyach, Jennifer; R. Furman, Richard; Liu, Ta-Ming; Gülçin Özer, Hatice; Zapatka, Marc; S. Ruppert, Amy; Xue, Ling; Hsieh-Hsin Li, Daniel; Steggerda, Susanne; Versele, Matthias; S. Davé, Sandeep; Zhang, Jenny; Selen Yilmaz, Ayse; Jaglowski, Samantha; A. Blum, Kristie; Lozanski, Arletta; Lozanski, Gerard; F. James, Danelle; C. Barrientos, Jacqueline; Lichter, Peter; Stilgenbauer, Stephan; J. Buggy, Joseph; Chang, Betty; J. Johnson, Amy; C. Byrd, John

doi:10.1056/nejmoa1400029

Public

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

Published in New England Journal of Medicine • May 28, 2014

Authors:

Jennifer A. Woyach

Richard R. Furman

Ta-Ming Liu

Abstract

BACKGROUND: Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK) and is effective in chronic lymphocytic leukemia (CLL). Resistance to irreversible kinase inhibitors and resistance associated with BTK inhibition have not been characterized. Although only a small proportion of pat...

Subject

Ibrutinib

Bruton's tyrosine kinase

Tyrosine kinase

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!